Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TODAY ???? HOW ABOUT THE PAST YEAR OR TWO .......
GWEN....
THANKS FOR THE PM .BEEN A ROUGH WEEK FOR ME .. 5 EYE DOCTORS .. EVERYONE HAD ME TRYING TO FILL OUT NEW PATIENT FORMS ..TRY DOING THAT SHIT OUT OF ONE EYE ...PPHM MAY NEVER GET OFF IT'S ASS I FEAR .. THE PEOPLE RUNNING IT ARE NOT INTERESTED IN SHAREHOLDERS ...HAVE A GREAT WEEKEND AND TAKE A BREAK FROM THESE BULLCRAP BOARDS .........JAKE
THE ANSWER WAS IN THE LAST PARAGRAPH .....
why no institutional ownership? why a three person penny stock bod? why a ceo that has never done a deal? until the ship rights itself we will continue to flounder.. the only people that can fix the problem are the problem.. that is the problem..
Avid Bioservices to Make Three Presentations at IBC's Biopharmaceutical Development and Production Week Conference Highlighting Its Innovative Applications for Developing Purification Methods and Quantitative Analytical Assays to Achieve and Monitor Manufacturing Consistency
-- Optimizing Purification Techniques To Remove Process-Related Impurities With No Impact On Critical Quality Attributes --
-- Strategies For Developing Process-Specific Host Cell Protein Antigens That Can Be Used For The Development Of Impurity Assays --
TUSTIN, CA - March 31, 2015 -- Avid Bioservices, Inc., the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc., today announced that it will present three posters at IBC's Biopharmaceutical Development and Production Week Conference to be held in Huntington Beach, California, March 30-April 2, 2015. These presentations will highlight Avid's expertise in optimizing purification techniques to remove process-related impurities, as well as strategies for developing process-specific host cell protein antigens that can be used for the development of impurity assays.
Avid will present the following posters, which will be on display Wednesday, April 1st and Thursday, April 2nd at the Hyatt Regency Huntington Beach Resort and Spa Hotel:
"Generation of Host Cell Protein Assay Reagents for Development of a Process-Specific Host Cell Protein Assay"
Presented by Jeanette Doerr, Ph.D., Senior Scientist, Molecular Cell Biology
"Variability of Triton X-100 Impacts Product Solution Clarity During Solvent/Detergent Treatment"
Presented by David Briggs, Ph.D., Associate Scientist, Manufacturing Science and Technology
"Reducing Residual DNA with No Impact on Critical Quality Attributes: A Case Study Using Modified Ceramic Hydroxyapatite (CHT) Conditions to Selectively Remove Host Cell DNA Contaminants"
Presented by Payam Farahani, Associate Scientist, CMC & Process Sciences
"In one case study, the Avid teams share examples of process improvements made by applying innovative techniques for purification, while maintaining critical quality attributes (CQAs). We have been able to make significant advancements in purification techniques for complex glycoproteins in order to meet the specific needs of our client's advancing programs," said Connie Chang, senior director of CMC and Process Sciences for Avid Bioservices. "In another case study, we share strategies for generating process specific Host Cell Proteins (HCP) that can be used to develop reagents for process specific impurity assays. Host cell proteins contaminants for biological products are of significant interest to regulatory agencies and this presentation shares our experience in developing the reagents that can be used to develop process specific HCP assays for late stage development and commercialization."
"Increasing the consistency of manufacturing processes is critical for our clients. This is achieved by better understanding the critical process parameters, including the materials used during production and by making adjustments that do not effect critical process characteristics." said Gene Yoshioka, senior director of manufacturing for Avid Bioservices. "One of the case studies being presented demonstrates the potential impact that raw material quality can have on cGMP production. Through better process understanding, we are able to achieve consistent process performance and a high level of quality for the products delivered to our clients."
In addition, Avid Bioservices will host conference attendees in booth #114 in the exhibition hall Monday, March 30th - Thursday, April 2nd.
For more information on IBC's Biopharmaceutical Development & Production Week Conference, please visit: http://www.ibclifesciences.com/BDPWeek/overview.xml
About Avid Bioservices
Avid Bioservices provides a comprehensive range of high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, final product filling, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
For further information please contact:
Chris Keenan or Kelly Pisarev Lord
(800) 987-8256
TO THE ONES WHO HAVE BEEN IN POS THE LONGEST /........
WE HAVE ALL BEEN THRU THIS MANY TIMES BEFORE .. IT DOESN'T MAKE ANY DIFFERENCE HOW MANY SPECIAL FRIENDS YOU HAVE OR SPECIAL ARTICLES YOU WRITE ..THIS IS PPHM AND IT JUST CONTINUES ON AND ON .. I SPENT THE DAY WITH A RETINOLOGIST LEARNING I AM IN A LOT OF TROUBLE WITH MY EYE TODAY .. I WASN'T ON THE COMPUTER ALL DAY AND WHEN I DID TURN IT ON ,IT WAS THE SAME AS IT ALWAYS IS .."A GIGNTIC P.O.S."
LEAVE THAT OTHER BOARD TO ALL THE PRETENDERS OVER THERE WHO THINK THEY KNOW IT ALL BUT ARE REALLY JUST SHITTING ON THE OTHERS AND GO OUT AND ENJOY THINGS INSTEAD OF A FLAT ASS FROM SITTING AND WATCHING A LUNATIC MESSAGE BOARD ....
Obama Release Of Secret Report On Israel Nukes Betrays Ally
Traffic passes by a sign showing the direction to Israel's Sorek nuclear reactor, near the central Israeli town of Yavne. Israel’s nuclear...
Traffic passes by a sign showing the direction to Israel's Sorek nuclear reactor, near the central Israeli town of Yavne. Israel’s nuclear... View Enlarged Image
Mideast: Quietly, the Obama administration has released details of Israel's nuclear program through the Defense Department. It was no accident, and could have a devastating impact on the balance of power in the region.
The same administration that refused to divulge what's in its soon-to-be-concluded nuclear "deal" with Iran, last month stealthily released a top-secret 1987 report on Israel's nuclear program — information that might be used by Israel's enemies.
The 386-page report "describes in detail the march of Israeli military and technological advancement in the 1970s and '80s," wrote journalist Michael Karpin on the Jewish Daily Forward's blog site.
Karpin, author of the "The Bomb in the Basement — How Israel Went Nuclear and What That Means for the World," says the U.S. report pays "particular attention to the development and progression of Israel's nuclear infrastructure and research labs."
The 27-year-old classified report further hints that Israel was developing a hydrogen bomb, with power a thousand times greater than a regular atomic bomb.
"It should be emphasized that in the history of the relations between the two countries," wrote Karpin, "there is no other published official American document that mentions in any way the Israelis' development of hydrogen bombs." That's how unusual this is.
Of course, Israel's nuclear prowess is an open secret. But the details have heretofore been largely unknown — something that's called "constructive ambiguity" in nuclear diplomacy. Keep your enemy guessing.
As such, Obama's petulant move is clearly intended to weaken Israel and make it vulnerable. There is no other rational basis for doing this.
And, by the way, it's only the latest in a series of childish attacks by Obama on Israel, America's one true ally in the Mideast and the only country in the region to give all of its citizens full democratic and legal rights.
Ratcheting up the rhetoric, the administration just this week absurdly accused Israel of spying on talks with Iran so that Israeli Prime Minister Benjamin Netanyahu could better argue against the talks' likely outcome — which is that Iran will eventually get a nuclear bomb.
Funny, we always thought that gathering information about what your enemy is up to isn't called spying, but intelligence gathering. That's what our own embassies do, routinely. Are they guilty of espionage too?
More seriously, by undercutting an ally that's threatened with extermination by the far-larger Iran, Obama betrays not just Israel, but America's own interests too.
Obama's recent actions, sadly, confirm the great Mideast scholar Bernard Lewis' dictum: "America is harmless as an enemy, (but) treacherous as a friend."
Simply put, who will trust us after such behavior?
As for the president, we have to wonder: Is this mere incompetence or intentional
Read More At Investor's Business Daily: http://news.investors.com/ibd-editorials/032615-745366-was-release-of-nuke-report-meant-to-aid-terrorist-iran-.htm#ixzz3VeJ71r7u
Follow us: @IBDinvestors on Twitter | InvestorsBusinessDaily on Facebook
Your tax dollars at work..........
Just a quick update, as you organize to file your income taxes, on the Obama family's lavish travel expenses that your money is underwriting. Financing might be a better word.
Barack and Michelle Obama have traveled more than any other first couple -- doing Spain, Africa, China, South America, among other distant spots. Often they're accompanied by friends and Michelle Obama's Mom, Marian Robinson, who's been living in the White House at taxpayer expense since her son-in-law's inauguration. And in some cases, Mrs. Robinson's friends tag along.
By one accounting, as of last July the Obamas had spent more than $44.4 million in taxpayer money on travel for 31 international trips lasting 119 days. For comparison, at the same point in his presidency Ronald Reagan had made 14 trips lasting 73 days.
You may recall Michele Obama's controversial trip with friends to Spain's luxury Costa del Sol in 2010 at a time when the U.S. unemployment rate was 9.5% on the way to 9.8%. And President Obama's $1 trillion economic stimulus package had yet to kick in. Of course, it's still yet to kick in.
According to numbers gathered by Judicial Watch, the public interest group that investigates government corruption, that trip cost Americans at least $468,000.
Turns out, by Obama administration standards that was a bargain tour.
Mrs. Obama's latest foreign junket this month was to Japan and Cambodia, allegedly to promote an Agency for International Development program to encourage education for girls.
On a one-day, side-trip to visit two shrines in Kyoto, including one honoring a god of rice, Michelle Obama's party incurred almost $79,000 in expenses just for rental cars, Judicial Watch reports. That's a lot of tuition for girls! Or boys.
When the Obamas visited Northern Ireland in 2013, Michelle Obama took her daughters on a two-day, side-trip to Dublin. That side-trip alone cost U.S. taxpayers a quarter-million dollars, including a $3,300-a-night hotel suite of the sort Mrs. Obama prefers. The Obamas' Ireland trip set us back just under $8 million.
Dublin rental cars alone for the first lady cost $114,000.
In 2014 when Mrs. Obama, her mother and daughters toured China, she stayed in Beijing's Westin Hotel in a suite costing you $8,400 per night. Previously, that price was deemed too expensive for Vice President Joe Biden to use.
However, JB does OK. On a European jaunt two years ago Biden and his unusually large entourage had a hotel bill in London of $460,000 for one night.
The next night in Paris, the vice presidential party -- and we do mean party -- ran up one-night hotel charges of $585,000.50. Now, that's a lot of mini-bar items and in-room movies.
Oh, and both those government hotel contracts were done on a no-bid basis, eliminating messy competition and cost-cutting. Can we afford these last 666 days?
Read More At Investor's Business Daily: http://news.investors.com/politics-andrew-malcolm/032515-745018-michelle-obama-travel-expenses.htm#ixzz3VX3A5ipL
Follow us: @IBDinvestors on Twitter | InvestorsBusinessDaily on Facebook
GWEN ..
THANKS FOR LETTING ME KNOW .. I WAS OUT FOR THE DAY ..
LEMMY ...I ANSWERED YOUR POST ABOUT EB AND POSTED IT TO POS BOARD BY MISTAKE AND IT GOT DELETED .....LOL FIGURES
TT...$50.00 ?? THAT NEVER HAPPENED
TRUER WORDS WERE NEVER SPOKEN IFU ...GOOD POST
I KEEP MY CORE HOLDINGS AND HAVE A BUNCH I TRADE WITH EVERY YEAR ..
I HAVE LEARNED OVER THE YEARS THATS THE WAY TO GO ..MADE SOME NICE TRADES FOR VACATIONS AND GOLF CLUBS THAT NEVER SEEMS TO DO WHAT THEY SAY THEY WILL , SORT OF LIKE THIS COMPANY ..MAYBE MY PATIENCE WILL PAY OFF SOMEDAY OR MY GRAND CHILDREN WILL BE VERY HAPPY CAMPERS..
I'M 22 1/2 YEARS .........
DOES THAT COUNT ...LOTS OF NEW PEOPLE HERE QUESTION THINGS THEY KNOW NOTHING ABOUT ......MOSY PROBABLY NEVER EVEN HEARD OF TARVACIN ...LOL
THEY TRASH PEOPLE WHO HAVE SUFFERED FOR YEARS BUT THATS THEIR THING I GUESS ...
Stocks sold off on Thursday — except for the one sector people are calling a bubble
Business Insider
By Akin Oyedele 17 hours ago
(Bloomberg)
The iShares Nasdaq Biotechnology ETF over 12 months Stocks sold off on Thursday after a post-Fed rally on Wednesday.
But the Nasdaq still gained ground thanks to the biotech sector which gained about 2% on Thursday.
In fact, biotech stocks have been on fire all year. They're up about 15% year-to-date.
Last month, Max Nisen at Quartz wrote that while everyone is focusing on massive tech valuations, the biotech industry is where things are getting really bubbly.
Nisen wrote: "Big pharma firms and investors have been showering billions on speculative companies that have never produced a viable drug. For four years running, biotech stocks have risen faster than any other sector of the market in the United States."
And in testimony to Congress last year, Federal Reserve chair Janet Yellen warned about stretched stock valuations, saying:
"Valuation metrics in some sectors do appear substantially stretched — particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year."
Biotech stocks have rallied by more than 50% since Yellen said that.
In Oppenheimer's latest weekly market strategy note, John Stoltzfus wrote that on a road trip visiting financial advisors across America last week, one of the most-asked questions was whether the biotech rally is over-extended.
Stoltzfus is in on this rally:
"Health Care is the only defensive sector that we really like. The baby boomer demographic, advancements in biotech, M&A activity, global health care mandates and increasing demand for ethical pharmaceuticals from the emerging and frontier markets are among the trends that cause us to rank the sector among our favorites."
But he notes that the sector can also be incredibly volatile:
"Last year the market signaled when Biotech had become overvalued and the group sold off. Dramatic developments in the sector along with M&A activity and a degree of animal spirits which from time to time flow through the category require investors to acknowledge the built-in risk along with the opportunities."
The sector is on fire, and nobody is quite sure when it will hit the top.
$1.52 UP ........332,600 SHARES TRADED
LOL..GO FOR IT .......
I STOOD UP FOR YOU AGAINST A FEW OF THE SLEEZEBALLS THAT WERE TRASHING YOU LAST NIGHT AND THEY DELETED MY POSTS...
LEMMY, LEMMY LEMMY .........
NOW WHY WOULD YOU SAY THAT WHEN YOU HAVE SO MANY PEOPLE ON POS BOARD WHO LOVE AND ADMIRE YOU ... YOU SHOULD APPLY TO BE A MOD OVER THERE .............LOL
15 immigrants protected from deportation arrested in sweep
Associated Press
By ALICIA A. CALDWELL 11 hours ago
House Judiciary Committee Chairman Bob Goodlatte, R-Va., speaks with reporters at the Capitol in Washington. Federal agents in a sweep targeting the most dangerous criminal immigrants arrested 15 people who have been allowed to remain in the U.S. under President Barack Obama's executive action intended to protect children who came to the U.S. years ago with their parents, The Associated Press has learned. With few fraud detection measures and effective background checks in place, its no surprise that ICE arrested over a dozen DACA recipients last week, most of whom had already been convicted of a crime, said Goodlatte. I and other members of the House Judiciary Committee have expressed concern about this for years.
WASHINGTON (AP) — Federal agents in a sweep targeting the most dangerous criminal immigrants arrested 15 people who have been allowed to remain in the U.S. under President Barack Obama's executive action intended to protect children who came to the U.S. years ago with their parents, The Associated Press has learned.
Fourteen of the 15 had been convicted of a crime, the Homeland Security Department confirmed late Thursday. In at least one case, the Obama administration renewed the protective status for a young immigrant after that person's conviction in a drug case, a U.S. official briefed on the arrests said.
One of the eligibility requirements for the program is that immigrants not have a criminal history. The official spoke on condition of anonymity because this person was not authorized to discuss the matter by name.
It was not immediately clear when 13 of the immigrants were convicted or what their crimes were. They were arrested by U.S. Immigrations and Customs Enforcement. The answers to those questions could undermine the integrity of the government's program, since eligibility is reserved for ambitious, young immigrants enrolled in school or who graduated and who would benefit American society.
None of the names of the immigrants was disclosed. One of the young immigrants arrested hadn't been convicted of a crime, but was arrested after being found armed with a gun, the official said.
MUCH MORE SELLING THAN BUYING .....SAME OLD,SAME OLD....
After Hours Time (ET) After Hours Price After Hours Share Volume
16:34 $ 1.49 High 1,500
16:28 $ 1.45 Low 5,897
16:26 $ 1.4502 1,977
16:00 $ 1.45 1,422
Read more: http://www.nasdaq.com/symbol/pphm/after-hours#ixzz3UCq2JYqq
TUSTIN, Calif. (AP) _ Peregrine Pharmaceuticals Inc. (PPHM) on Thursday reported a loss of $13 million in its fiscal third quarter.
On a per-share basis, the Tustin, California-based company said it had a loss of 8 cents.
The pharmaceutical posted revenue of $5.7 million in the period.
In the final minutes of trading on Thursday, the company's shares hit $1.45. A year ago, they were trading at $2.33.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PPHM at http://www.zacks.com/ap/PPHM
TUSTIN, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced financial results for the third quarter of fiscal year (FY) 2015 ended January 31, 2015. The company also provided an update on its advancing clinical pipeline and reviewed other corporate developments.
"This is an exciting time for the company on many fronts. Our lead clinical program, bavituximab is in a unique position as a Phase III immuno-oncology agent that has shown great potential in combination with both current standard cancer treatments, such as chemotherapy, as well as emerging immuno-oncology agents such as those targeting PD-1 and PD-L1. We have continued to advance the bavituximab Phase III SUNRISE trial and are on track to complete enrollment in the study by year-end," said Steven W. King, president and chief executive officer of Peregrine. "Aside from completing enrollment in the SUNRISE trial, our clinical focus is to enter into new clinical collaborations to further explore the combination potential of bavituximab with anti-PD-1 and PD-L1 in multiple tumor indications and we expect these activities to be quite visible over the coming months as the planning that is underway now, comes to fruition. These efforts, on top of completing the Avid capacity expansion and continued revenue growth, point to many important milestones throughout remainder of 2015."
The company's mission is to develop a brand new class of immunotherapies focused on the clinical advancement of our lead drug candidate bavituximab which targets the immunosuppressive PS signaling pathway. Bavituximab has the potential to be an effective part of treatment regimens in many different tumor types and has recently shown promise in combination with other immuno-oncology compounds in multiple preclinical models of cancer. Over the past quarter, the company has made important progress in bringing this novel immunotherapy closer to the market led by the SUNRISE Phase III clinical trial.
The company continues to enroll patients in the SUNRISE (Stimulating ImmUne RespoNse thRough BavItuximab in a PhaSE III Lung Cancer Study) trial. SUNRISE is a Phase III, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, tolerability and efficacy of bavituximab as a second-line treatment in patients with non-squamous, non-small cell lung cancer (NSCLC). The trial is evaluating bavituximab plus the standard chemotherapy docetaxel versus docetaxel plus placebo in approximately 600 patients at clinical sites worldwide. Patients with Stage IIIb/IV non-squamous NSCLC who have progressed after standard front-line treatment are eligible for enrollment. The primary endpoint of the trial is overall survival. The company anticipates completing patient enrollment in the SUNRISE trial by the end of calendar year 2015. For additional information about the SUNRISE trial, please visit www.sunrisetrial.com or ClinicalTrials.gov using the Identifier NCT01999673.
The company's commitment to exploring the full clinical potential of bavituximab in combination with chemotherapies or other immuno-oncology agents is being executed through a series of Investigator-Sponsored Trials (IST) in multiple solid tumor indications. The following represents anticipated upcoming data from ongoing or completed clinical studies as well as the status of trials that can yield data in the future:
Final data from a Phase I IST that evaluated bavituximab in combination with paclitaxel in patients with HER2-negative metastatic breast cancer has been accepted for publication in the peer-reviewed journal Cancer Medicine and will be published online in the coming weeks. The company is currently evaluating opportunities to advance the clinical development of bavituximab in breast cancer.
Data from a Phase II IST that evaluated bavituximab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC), or liver cancer, presented at the 2015 Gastrointestinal Cancers Symposium Data show that the combination of bavituximab and sorafenib is associated with an improved time to progression (TTP) of 6.7 months, a disease specific survival (DSS) of 8.7 months, a disease control rate (DCR) of 58% (22 out of 38 patients) and a 4-month progression-free survival (PFS) of 62%. Two patients (5%) achieved a partial response according to Response Evaluation Criteria In Solid Tumors (RECIST). The secondary endpoint of median overall survival (OS) was 6.2 months. The combination of bavituximab and sorafenib was well-tolerated in patients with advanced HCC with no indications of autoimmune adverse events that have been seen with other checkpoint immunotherapies. During the quarter, translational data from six patients from this trial were presented at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting and Associated Programs. These data, to assess and measure changes in immune response pre- and post-treatment, show the ability of bavituximab to positively regulate an increase in tumor fighting immune cells (particularly CD8 T cells) following one cycle of treatment, thus further confirming in patients what has been shown for PS-targeting antibodies in multiple preclinical cancer models. This trial is also the subject of an oral presentation at the Society of Surgical Oncology's (SSO) 68th Annual Cancer Symposium to be held March 25-28, 2015 in Houston, Texas.
A Phase I IST evaluating bavituximab in combination with capecitabine and radiation therapy in up to 18 patients with Stage II or III rectal adenocarcinoma is open for patient enrollment.
A Phase Ib IST evaluating bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy®) in up to 24 patients with advanced melanoma is open for patient enrollment.
As part of the company's mission to discover the full potential of its immunotherapy bavituximab in clinical disease applications, the company is advancing studies through its Immuno-Oncology Development Program. This program is designed to explore the potential of combining bavituximab with other immunotherapies, experimental immuno-oncology drugs including checkpoint inhibitors, as well as vaccines.
During the quarter, data presented at the 2014 San Antonio Breast Cancer Symposium (SABCS) show that the monotherapy preclinical equivalent to bavituximab demonstrated statistically significant tumor growth inhibition in breast tumor models when compared to a control antibody. Data further show that this monotherapy yielded statistically significant increases in the percentage of tumor fighting T-lymphocytes and decreases in tumor inflammatory myeloid-derived suppressor cells (MDSC), all key indicators of immune activation.
Data presented recently at the Keystone Tumor Immunology meeting show that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 antibody displayed statistically significant improvement in tumor fighting immune cells, activation signals and cytokines in a model of melanoma compared to anti-PD-1 alone. Moreover, cells that suppress the immune system from recognizing tumors, such as MDSCs, were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone.
Peregrine announced today the acceptance of three posters at the American Association for Cancer Research's (AACR) Annual Meeting to be held April 18-22, 2015 in Philadelphia, Pennsylvania. These posters include preclinical data from the company's Immuno-Oncology Development Program of PS-targeting agents in combination with immune checkpoint inhibitors in breast cancer and melanoma, as well as translational research conducted with tumor tissue from lung cancer patients.
The company is also exploring other applications for the PS-targeting platform outside of cancer therapy. These activities include:
PS-TARGETING MOLECULAR IMAGING PROGRAM
The company is exploring the potential of its experimental PS-targeting molecular imaging candidate, 124I-PGN650, in patients with various solid tumor types. This is an open-label, single-center trial with a primary goal of estimating radiation dosimetry in critical and non-critical organs and secondary objectives of tumor imaging and safety.
AVID BIOSERVICES
Avid Bioservices, Inc. is the contract manufacturing subsidiary of Peregrine. Avid provides high quality clinical and commercial manufacturing services under cGMP for the biotechnology and biopharmaceutical industries. As announced in December, Avid is in the process of expanding its manufacturing capacity with a new state-of-the-art facility. Activities supporting this expansion continue and the company remains on track to commence manufacturing in the new facility during mid-2015.
"Our Avid business had another strong quarter further supporting our decision announced in December to expand our manufacturing capacity to meet the growing needs of our manufacturing business as well as the anticipated commercial launch of bavituximab," said Paul Lytle, chief financial officer of Peregrine. "Our current backlog for manufacturing services has increased to $29 million and we are increasing our revenue guidance from between $19 to $23 million to between $23 and $25 million for the full fiscal year 2015."
FINANCIAL RESULTS
Contract manufacturing revenue from Avid's clinical and commercial biomanufacturing services provided to its third-party customers for the third quarter FY 2015 were $5,677,000, compared to $3,885,000 for the same quarter of the prior fiscal year. In addition to providing biomanufacturing services to its third-party customers, Avid will continue to support the potential commercialization of bavituximab.
Total costs and expenses in the third quarter of FY 2015 were $18,699,000, compared to $13,628,000 in the third quarter of FY 2014. This increase was primarily attributable to the current quarter increases in research and development expenses associated with the SUNRISE Phase III trial and cost of contract manufacturing associated with higher contract manufacturing revenue, which were offset by the current quarter decrease in selling, general and administrative expenses. For the third quarter FY 2015, research and development expenses were $11,261,000, compared to $6,649,000 for the third quarter of FY 2014. For the third quarter of FY 2015, cost of contract manufacturing was $3,113,000, compared to $2,416,000 for the third quarter of FY 2014. For the third quarter of FY 2015, selling, general and administrative expenses were $4,325,000 compared to $4,563,000 for the third quarter of FY 2014.
Peregrine's consolidated net loss attributable to common stockholders was $14,027,000, or $0.08 per share, for the third quarter of FY 2015, compared to a net loss attributable to common stockholders of $9,724,000, or $0.06 per share, for the same quarter of the prior year.
Peregrine reported $55,238,000 in cash and cash equivalents as of January 31, 2015 compared to $77,490,000 at fiscal year ended April 30, 2014.
More detailed financial information and analysis may be found in Peregrine's Quarterly Report on Form 10-Q, which will be filed with the Securities and Exchange Commission today.
Conference Call
Peregrine will host a conference call and webcast this afternoon, March 12, 2015, at 4:30 PM EDT (1:30 PM PDT).
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals conference call.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company may experience delays in the enrollment of patients in the Phase III SUNRISE trial and may not achieve its anticipated enrollment timeline, the risk that the results from the Phase III SUNRISE trial may not support a future Biologics License Application (BLA) submission, the risk that the company may not have or raise adequate financial resources to complete the Phase III SUNRISE trial or additional clinical trials, such as a breast cancer trial, the risk that data from pre-clinical studies and early stage clinical trials, including ISTs, may not correlate with the results of later stage clinical trials, the risk that data from the company's Immuno-Oncology Development Program and/or translational studies may not correlate to the results of future clinical trials, the risk that Avid's revenue growth may slow or decline, the risk that Avid may experience technical difficulties in processing customer orders which could delay delivery of products to customers and receipt of payment, and the risk that one or more existing Avid customers terminates its contract prior to completion. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2014 as well as any updates to these risk factors filed from time to time in the company's other filings with the Securities and Exchange Commission. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Yervoy is a registered trademark of Bristol-Myers Squibb.
PEREGRINE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
THREE MONTHS ENDED JANUARY 31, NINE MONTHS ENDED JANUARY 31,
2015 2014 2015 2014
Unaudited Unaudited Unaudited Unaudited
REVENUES:
Contract manufacturing revenue $ 5,677,000 $ 3,885,000 $ 17,436,000 $ 15,820,000
License revenue -- -- 37,000 107,000
Total revenues 5,677,000 3,885,000 17,473,000 15,927,000
COSTS AND EXPENSES:
Cost of contract manufacturing 3,113,000 2,416,000 10,835,000 9,281,000
Research and development 11,261,000 6,649,000 31,465,000 18,910,000
Selling, general and administrative 4,325,000 4,563,000 13,503,000 12,913,000
Total costs and expenses 18,699,000 13,628,000 55,803,000 41,104,000
LOSS FROM OPERATIONS (13,022,000) (9,743,000) (38,330,000) (25,177,000)
OTHER INCOME (EXPENSE):
Interest and other income 29,000 23,000 108,000 68,000
Interest and other expense (1,000) (4,000) (1,000) (5,000)
NET LOSS $ (12,994,000) $ (9,724,000) $ (38,223,000) $ (25,114,000)
COMPREHENSIVE LOSS $ (12,994,000) $ (9,724,000) $ (38,223,000) $ (25,114,000)
Series E preferred stock accumulated dividends (1,033,000)
--
(2,577,000)
--
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (14,027,000) $ (9,724,000) $ (40,800,000) $ (25,114,000)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and Diluted 182,519,923 163,223,767 180,562,524 156,521,874
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.08) $ (0.06) $ (0.23) $ (0.16)
PEREGRINE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
JANUARY 31, 2015 APRIL 30, 2014
Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 55,238,000 $ 77,490,000
Trade and other receivables, net 6,284,000 1,332,000
Inventories 6,148,000 5,530,000
Prepaid expenses and other current assets, net 934,000 1,419,000
Total current assets 68,604,000 85,771,000
Property and equipment, net 8,958,000 2,447,000
Other assets 1,559,000 2,327,000
TOTAL ASSETS $ 79,121,000 $ 90,545,000
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 6,814,000 $ 2,434,000
Accrued clinical trial and related fees 3,117,000 4,433,000
Accrued payroll and related costs 3,716,000 3,837,000
Deferred revenue, current portion 5,752,000 5,241,000
Customer deposits 8,311,000 5,760,000
Other current liabilities 490,000 502,000
Total current liabilities 28,200,000 22,207,000
Deferred revenue, less current portion -- 292,000
Other long-term liabilities 1,127,000 347,000
Commitments and contingencies
STOCKHOLDERS' EQUITY:
Preferred stock- $0.001 par value; authorized 5,000,000 shares; issued and outstanding - 1,180,004 and 775,000, respectively 1,000 1,000
Common stock- $0.001 par value; authorized 325,000,000 shares; outstanding - 184,244,698 and 178,871,164, respectively 184,000 179,000
Additional paid-in capital 491,098,000 470,785,000
Accumulated deficit (441,489,000) (403,266,000)
Total stockholders' equity 49,794,000 67,699,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 79,121,000 $ 90,545,000
CONTACT: Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Peregrine Pharmaceuticals, Inc. Logo
Source: Peregrine Pharmaceuticals, Inc.
News Provided by Acquire Media
Close window | Back to top
delicious
Digg
Facebook
LinkedIn
Twitter
Copyright 2015 Peregrine Pharmaceuticals, Inc.
The Architect of Destruction
Maureen Scott is an ardent American patriot who was born in Pittsburgh, PA , and retired to Richmond , VA , in 2000. Free from the nine-to-five grind of writing for employers and clients, she began writing political commentary to please herself and express her convictions.
The accomplishment of which she is most proud is her volunteer work at an Army base where she looked into the eyes and hearts of the service members who protect our country.
Our Pledge of Allegiance, a military band playing the National Anthem, and the wisdom of our Founding Fathers, inspire her passion and views. Her life is guided by a firm belief that truth is the most important virtue, and that God knows what He is doing with her.
ABSOLUTELY NO ONE, could have described this President more accurately. This is a brief biography that articulates the man, his life and his goals perfectly!
The Architect of Destruction
By Maureen Scott
Barack Obama appears to be a tormented man filled with resentment, anger, and disdain for anyone of an opinion or view other than his. He acts in the most hateful, spiteful, malevolent, vindictive ways in order to manipulate and maintain power and control over others. Perhaps, because, as a child, he grew up harboring an abiding bitterness toward the U.S. That was instilled in him by his family and mentors…it seems to have never left him.
It is not the color of his skin that is a problem in America.
Rather it is the blackness that fills his soul and the hollowness in his heart where there should be abiding pride and love for this country.
Think: Have we ever heard Obama speak lovingly of the U.S. Or its people, with deep appreciation and genuine respect for our history, our customs, our sufferings and our blessings? Has he ever revealed that, like most patriotic Americans, he gets "goose bumps" when a band plays "The Star Spangled Banner," (no he gets goose bumps when he hears the ''Muslim call to prayer" (his words) or sheds a tear when he hears a beautiful rendition of " America the Beautiful?" Does his heart burst with pride when millions of American flags wave on a National holiday - or someone plays "taps" on a trumpet? Has he ever shared the admiration of the military, as we as lovers of those who keep us free, feel when soldiers march by? It is doubtful because Obama did not grow up sharing our experiences or our values. He did not sit at the knee of a Grandfather or Uncle who showed us his medals and told us about the bravery of his fellow troops as they tramped through foreign lands to keep us free. He didn't have grandparents who told stories of suffering and then coming to America, penniless, and the opportunities they had for building a business and life for their children.
Away from this country as a young child, Obama didn't delight in being part of America and its greatness. He wasn't singing our patriotic songs in kindergarten, or standing on the roadside for a holiday parade and eating a hot dog, or lighting sparklers around a campfire on July 4th as fireworks exploded over head, or placing flags on the grave sites of fallen and beloved American heroes.
Rather he was separated from all of these experiences and doesn't really understand us and what it means to be an American. He is void of the basic emotions that most feel regarding this country and insensitive to the instinctive pride we have in our national heritage. His opinions were formed by those who either envied us or wanted him to devalue the United States and the traditions and patriotism that unites us.
He has never given a speech that is filled with calm, reassuring, complimentary, heartfelt statements about all the people in the U.S. Or one that inspires us to be better and grateful and proud that in a short time our country became a leader, and a protector of many. Quite the contrary, his speeches always degenerate into mocking, ridiculing tirades as he faults our achievements as well as any critics or opposition for the sake of a laugh, or to bolster his ego. He uses his Office to threaten and create fear while demeaning and degrading any American who opposes his policies and actions. A secure leader, who has noble self-esteem and not false confidence, refrains from showing such dread of critics and displaying a cocky, haughty attitude.
Mostly, his time seems to be spent causing dissension, unrest, and anxiety among the people of America, rather than uniting us (even though he was presented to us as the "Great Uniter"). He creates chaos for the sake of keeping people separated, envious, aggrieved and ready to argue. Under his leadership Americans have been kept on edge, rather than in a state of comfort and security. He incites people to be aggressive toward, and disrespectful of, those of differing opinions. And through such behavior, Obama has lowered the standards for self-control and mature restraint to the level of street-fighting gangs, when he should be raising the bar for people to strive toward becoming more considerate, tolerant, self-disciplined, self-sustaining, and self-assured.
Not a day goes by that he is not attempting to defy our laws, remove our rights, over-ride established procedures, install controversial appointees, enact divisive mandates, and assert a dictatorial form of government.
- Never has there been a leader of this great land who used such tactics to harm and hurt the people and this country.
- Never have we had a President who spoke with a caustic, evil tongue against the citizenry rather than present himself as a soothing, calming and trustworthy force.
- Never, in this country, have we experienced how much stress one man can cause a nation of people - on a daily basis!
Obama has promoted the degeneration of peace, civility, and quality of cooperation between us. He thrives on tearing us down, rather than building us up. He is the Architect of the decline of America, and the epitome of a Demagogue.
© Maureen Scott Truth or Fiction verified--2013
Snopes also
MADE A FEW BUYS TODAY IN THE 8.50'S ON PAAS.......
SOLD IT ALL IN THE 8.90'S NICE ..............
DO I WANT TO BUY MORE POS ?? NOT TODAY .....LOL
RE:My First Post...but I have been lurking for over a year....
OVER A YEAR ?? YOU JUST SIGNED UP 2 DAYS AGO ......
LEMMY IS A DISGRUNTLED SHAREHOLDER BUT..
HE HAS BEEN A SHAREHOLDER SINCE THE RB DAYS , LONGER THAN MOST HERE .. HE HAS A RIGHT TO SPEAK OUT ABOUT HIS FRUSTRATIONS JUST LIKE OTHERS WHO TOUT A SMALL MOVE UP LAST WEEK LIKE IT'S GOING TO THE MOON ..WE ALL REACT IN DIFFERENT WAYS BUT I CAN ASSURE YOU HE WANTS PPHM TO SUCCEED AS MUCH AS ANYONE ..WHAT HAPPENED LAST WEEK USUALLY HAPPENS ONCE OR TWICE EVERY YEAR WITH THIS STOCK .. I HAVE BEEN IN IT 22 PLUS YEARS AND I JUST LEARNED HOW TO SELL SOME INTO THESE MOVES AND BUY BACK THE NEXT WEEK ..I MAKE ENOUGH EVERY TIME TO TAKE A NICE VACATION EVERY YEAR AND I HOLD ENOUGH TO BE A WEALTHY MAN IF AND WHEN IT DOES "GO TO THE MOON". YOU WILL LEARN TO UNDERSTAND THIS COMPANY IF YOU STAY AROUND LONG ENOUGH ....GLTY
LOOKS LIKE I DID WELL SELLING AT 1.61 .
I WILL BE BUYING MOST BACK IN THE 1.30'S TOMORROW AND IN THE DAYS TO COME ....... POS NEVER CHANGES IT'S SPOTS IT SEEMS ....
ALL IN ALL.........
JUST ANOTHER BRICK IN THE WALL ..........GLTY JIM
NO VOLUME ?????
FROM THIS
Date Volume
Mar 9, 2015 2,306,600
Mar 6, 2015 3,122,400
Mar 5, 2015 3,183,500
Mar 4, 2015 1,100,400
Mar 3, 2015 2,234,800
Mar 2, 2015 1,720,100
Feb 27, 2015 4,461,500
Feb 26, 2015 2,876,200
Feb 25, 2015 1,028,700
TODAY SO FAR ....290,828
I AM FEELING LIKE A GENIUS TODAY .....
I SOLD A BUNCH LAST WEEK AT 1.61 ........
WILL BUY BACK IN THE 1.40 / 1.35 RANGE ...IT NEVER CHANGES WITH THIS PPHM/POS ..........
I STILL OWN ENOUGH TO BE VERY HAPPY IF IT EXPLODES ....LOL
I HOPE YOUR CORRECT CP BUT HISTORY SAYS OTHERWISE..
DOWN 6% .........
AND KING HASN'T SPOKE YET ......
Nine Important Facts to Remember as We Grow Older:
Number 9 - Death is the number 1 killer in the world.
Number 8 - Life is sexually transmitted.
Number 7 - Good health is merely the slowest possible rate at which one can die.
Number 6 - Men have two emotions: hungry and horny, and they can't tell them apart. If you see a gleam in his eyes, make him a sandwich.
Number 5 - Give a person a fish and you feed them for a day. Teach a person to use the Internet and they won't bother you for weeks, months, maybe years.
Number 4 - Health nuts are going to feel stupid someday, lying in the hospital, dying of nothing.
Number 3 - All of us could take a lesson from the weather. It pays no attention to criticism.
Number 2 - In the 60's, people took acid to make the world weird. Now the world is weird, and people take Prozac to make it normal.
Number 1 - Life is like a jar of jalapeno peppers. What you do today might burn your ass tomorrow.
...and as someone recently said to me:
Don't worry about old age; it doesn't last that long.
AND SHE MAY STILL HAVE SOMETHING OF INTEREST IN PPHM IMHO..
Venture Capital A-C
www.njinsider.com, 5 Jan 2010 [cached]
Jennifer H. Lobo President
Established 1990 by JENNIFER LOBO, former partner in DOMAIN ASSOCIATES venture capital firm, to provide investment banking, merger acquisition services for firms involved in biotechnology> Assists in raising capital, mergers and acquisitions, divestitures of biotechnology firms and assets> Represents large corporations seeking biotechnology licenses, products, acquisitions, and smaller firms seeking capital.
YOU JUST NEVER KNOW THESE DAYS .....LOL
Mrs. Buhl was also the CEO, President, and Founder of Peregrine Pharmaceuticals, Inc., which was one of the first companies to identify the importance of the tumor vasculature for tumor growth and metastasis.
HER MARRIED NAME WAS BUHL.........
Jennifer Lobo Buhl, a Southampton resident, is Co-Founder of Dihedron Inc., a company developing small molecule drugs that exploit natural mechanisms in the human cell to deliver greater concentrations of a drug to its intended site of action.
Mrs. Buhl was also the CEO, President, and Founder of Peregrine Pharmaceuticals, Inc., which was one of the first companies to identify the importance of the tumor vasculature for tumor growth and metastasis.She has acted as business advisor and director for GeneScreen/Molecular Tool, a genomics company which merged with Orchid Biocomputer two years ago.Mrs. Buhl served as President and Founder of Biotechnology Financial Corporation, General Partner and Founder of Domain Associates, a venture capital firm for biotech companies.
ARE YOU GUYS FORGETTING ???
THE FAMOUS JOHN BONFIGLIO AND JENNIFER LOBO
HE HAS BEEN IN PPHM AS LONG AS ME ...OVER 22 YEARS .
AKA ....NOTBOB17